Read more about the article Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

Continue ReadingKadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85
Read more about the article Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2

Continue ReadingOramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2